TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07080385: Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)

Sponsor: Calcilytix Therapeutics, Inc., a BridgeBio company · Phase: PHASE2/PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 28 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$1,336,632

Rescue Site Savings

+$891,088

Unlock Full NCT07080385 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07080385 Rescue Dossier →